Aeterna Zentaris (AEZS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Aeterna Zentaris Reports Second Quarter Financial and Operating Results
August 13, 2015 4:15 PM EDTStrong fundamentals; pace of transformation accelerates; dilution negatively impacts stock price
All amounts are in US Dollars
Second quarter key developments
Data and Safety Monitoring Board recommends continuation of ZoptEC Phase 3 study of zoptarelin doxorubicin; patient enrollment completed; second interim results expected in early October 2015 Macrilen confirmatory Phase 3 study initiated Saizen® co-promotion agreement concluded; promotional activities launched on July 27, subsequent to quarter-end Global optimization program successfully completed; significant reduction of expenses at Frankfurt office through lease... More